

The logo for Seeking Alpha, with the text 'Seeking Alpha' in white and a yellow Greek letter alpha symbol to the right, all on a dark red background.

## Boston Scientific Corporation Q4 2008 Earnings Call Transcript

### Question-and-Answer Session

---

#### Operator

(Operator instructions) Our first question comes from the line of Bob Hopkins with Banc of America/Merrill Lynch. Please go ahead.

#### Bob Hopkins – Banc of America/Merrill Lynch

Thank you and good morning.

#### Sam Leno

Good morning, Bob.

#### Bob Hopkins – Banc of America/Merrill Lynch

I have one quick housekeeping question and then I will get to my queue. Sam, can you translate your guidance for us into GAAP numbers for 2009? GAAP EPS for 2009?

#### Sam Leno

Didn't I do that?

#### Bob Hopkins – Banc of America/Merrill Lynch

I'm sorry. I was hopping between calls. I'm sorry if I didn't get that.

#### Sam Leno

Looks like I have it handy here. So GAAP on the low end will be \$0.56 and the high end, \$0.68.

#### Bob Hopkins – Banc of America/Merrill Lynch

Okay. Great. And then for, Jim, two things, one, can you help us understand what kind of Cardiac Rhythm Management market growth assumptions you're assuming for 2009 and then also if you wouldn't mind providing us with any incremental data points that you might have to give us confidence in your ability to get the necessary stent approval in Europe by the end of the year to assume a smooth transition with Abbott? Thank you.

#### Jim Tobin

We're looking at same market everybody else is. We see sort of 5% to 8% overall market growth. That's a little less than I would have said maybe a year ago. I think it was talking about 7% to 9%, so it's probably moderated a little bit, but it's still healthy growth. And most importantly, worldwide we're starting from a share – overall share point of 21% or something like that. And so we don't have to gain tons of share to see double-digit sales growth, particularly on top of even a 5% market growth. So, so net-net, we look for our CRM business to grow double digits on the basis of all these new products for a while.

As far as how we're doing on the introduction of PROMUS element, we're actually I think ahead of schedule. I'm very confident that we're going to accomplish that in Europe by the end of this year. I know we're ahead of schedule on the 2012 time lines for U.S. and Japan, and so I'm not going to go into any detail but if we – if I weren't confident, I would tell you and I am confident that we are on or ahead worldwide.

Copyright © 2008 CNET Networks, Inc. All Rights Reserved.